X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds of the Private Placement are expected to be used for certain Phase 3 drug development activities for CYB003, a proprietary deuterated psilocybin analog in development for the potential treatment of Major Depressive Disorder.
Lead Product(s): Deuterated Psilocybin Analog
Therapeutic Area: Psychiatry/Psychology Product Name: CYB003
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bloom Burton Securities Inc
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement March 19, 2024
Details:
CYB004 (deuterated dimethyltryptamine) is a 5-HT2A receptor agonist, which is being evaluated in phase 2 clinical trials for the treatment of generalized anxiety disorders.
Lead Product(s): Deuterated Dimethyltryptamine
Therapeutic Area: Psychiatry/Psychology Product Name: CYB004
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 15, 2024
Details:
The net proceeds of the Private Placement are expected to be used for certain Phase 3 drug development activities for CYB003, a proprietary deuterated psilocybin analog in development for the potential treatment of Major Depressive Disorder.
Lead Product(s): Deuterated Psilocybin Analog
Therapeutic Area: Psychiatry/Psychology Product Name: CYB003
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Deep Track Capital
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement March 13, 2024
Details:
CYB003 a proprietary deuterated psilocybin analog, today received FDA breakthrough therapy designation, it is currently being development for the treatment of Major depressive disorder.
Lead Product(s): Deuterated Psilocybin Analog
Therapeutic Area: Psychiatry/Psychology Product Name: CYB003
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 13, 2024
Details:
CYB004 (deuterated dimethyltryptamine) is a 5-HT2A receptor agonist, which is being evaluated in phase 1/2 clinical trials for the treatment of generalized anxiety disorders.
Lead Product(s): Deuterated Dimethyltryptamine
Therapeutic Area: Psychiatry/Psychology Product Name: CYB004
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 23, 2024
Details:
CYB004 is a synthetic deuterated N, N-Dimethyltryptamine (DMT) analog which is under phase 1/2 clinical development for the treatment of generalized anxiety disorder (GAD) with depressive symptoms.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Psychiatry/Psychology Product Name: CYB004
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2024
Details:
CYB003 (deuterated psilocybin analog) is a small molecule oral agonist targeting the 5-HT2a receptor, it is being investigated for the treatment of Major Depressive Disorder.
Lead Product(s): Deuterated Psilocybin Analog
Therapeutic Area: Psychiatry/Psychology Product Name: CYB003
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2023
Details:
The Company intends to use the net proceeds for the progression of the Company’s CYB003 (deuterated psilocybin analog) for the treatment of major depressive disorder and its deuterated DMT programs.
Lead Product(s): Deuterated Psilocybin Analog
Therapeutic Area: Psychiatry/Psychology Product Name: CYB003
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alliance Global Partners
Deal Size: $64.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 10, 2023
Details:
CYB003 (deuterated psilocybin analog) is a proprietary molecule, which is being evaluated in phase 2 clinical trials for the potential treatment of major depressive disorder.
Lead Product(s): Deuterated Psilocybin Analog
Therapeutic Area: Psychiatry/Psychology Product Name: CYB003
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2023
Details:
Through the acquisition, combined portfolio will advance well-protected deuterated DMT program, including SPL026 (N,N-dimethyltryptamine) for the potential treatment of Major Depressive Disorder (MDD).
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Psychiatry/Psychology Product Name: SPL026
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Recipient: Small Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 23, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
